This site uses cookies. By using this site you agree to receiving cookies. View Policy.

125%

More people died from other respiratory problems than from Covid in 2020. Inbentus has the intention of democratising medical technology by developing low-cost respirators. The company is ready to commercialise its first respirator internationally and is developing the second piece of ICU equipment to cover some of the foreseen global demand of $12bn in 2027.

  • The global market for mechanical ventilators is estimated to grow at a 16% until 2027
  • The Ventilator market is expected to reach $12 billion by 2027 
  • The world population is expected to increase by 2 billion in the next 30 years
  • Granted financial aid for € 200K to non-refundable funds

Idea

Inbentus Video
SAV-19: COVID emergency respirator prototype
SAV-19: COVID emergency respirator prototype
SAV-19 display
SAV-19 display
The SAV-19 is competitively priced
The SAV-19 is competitively priced

Thousands of people die every day from a lack of medical respirators. These high-reliability devices are inaccessible to emerging markets due to their expense. COVID has made this problem worse.

Established at the beginning of 2020, we want to make respirators more accessible to less affluent populations. That's why we started INBENTUS.

In less than 1 month we've developed a COVID emergency respirator prototype that's competitively priced with the first units having been delivered to Latin American countries already.

Although our initial strategy is focused on COVID patients, several international studies indicate that respiratory pathologies will be a huge global problem over the next 20 years, due to:

- Increases in world population by almost 30%.

- Increases in life expectancy.

By 2027, €12bn+ euros are expected to be spent on respiratory medical technology which has sustained annual growth of 16%.

To meet this strong demand, we plan to start developing a new & improved high-performance respirator that's more inexpensive with the aim to achieve high penetration in Latin America & Africa in the coming years. Hospitals of public & private health networks are our main targets to obtain revenue.

Funds will be used to boost sales and complete authorization of our existing respirator, launch local campaigns in target countries and to develop our new, high-performance respirator product.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

To see the rest of the INBENTUS pitch, join now. It's free, quick and easy.

Due to financial regulations, you need to join our community to view the full investment opportunity.

Join

Already registered?
Log in

This pitch is approved by Crowdcube

This pitch is approved as a financial promotion by Crowdcube Capital Limited. Every pitch on Crowdcube is reviewed to ensure it is fair, clear and not misleading.

As part of our commitment to investor transparency, Crowdcube’s Due Diligence Charter outlines the analysis and verification that is conducted on equity fundraises on Crowdcube by our legal and compliance professionals.

Read more

Risk warning

Investments of this nature carry risks to your capital, including illiquidity, lack of dividends and dilution. Balance risk with a diversified portfolio. Read more. Approved as a financial promotion by Crowdcube Capital Limited, which is authorised and regulated by the Financial Conduct Authority.

Investment opportunities are not offers to the public and investors must be eligible Crowdcube members. Further restrictions and Crowdcube's limitation of liability are set out in the Investor Terms and Conditions. Please seek independent advice as required as Crowdcube does not give investment or tax advice.